Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 18/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512864 | 1.00 | KRAS (0.50) | KRASESR2USP30 | |
| SCHEMBL23512677 | 0.91 | KRAS (0.45) | KRASESR2USP30 | |
| SCHEMBL23512966 | 0.91 | KRAS (0.45) | KRASESR2USP30 | |
| SCHEMBL29693188 | 0.89 | KRAS (0.50) | KRASESR2 | |
| SCHEMBL24558290 | 0.89 | KRAS (0.50) | KRASESR2 | |
| SCHEMBL29693111 | 0.87 | KRAS (0.42) | KRASESR2 | |
| SCHEMBL24558159 | 0.87 | KRAS (0.42) | KRASESR2 | |
| SCHEMBL23512570 | 0.87 | KRAS (0.49) | KRASESR2 | |
| SCHEMBL23513000 | 0.87 | KRAS (0.49) | KRASESR2 | |
| SCHEMBL23496661 | 0.85 | KRAS (0.55) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179633-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2021-06-17 | — | — | US | disclosed |
| WO-2021118877-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | KRAS 1/4885ESR2 1541/4885USP30 3416/4885 |
| US-11731984-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KRAS 1/4885ESR2 2072/4885USP30 2637/4885 |
| US-20210179633-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885ESR2 2072/4885USP30 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.